Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Mining Launches First Commercial Software Product

NEW YORK, April 17 – Molecular Mining of Raleigh, NC, said Tuesday it had launched its first commercial product, installing its GeneLinker Gold gene expression analysis software at a number of sites in Japan and North America. 

Since its launch in late 1999, Molecular Mining has used its data mining technology in collaborations with research partners, but GeneLinker Gold is the company’s first commercial software product. It enables data filtering and transformation, sorting and clustering, and classification and prioritization of genes along with a suite of visualization tools. 

GeneLinker Gold is the entry-level offering in a proposed line of gene expression analysis solutions that will also include GeneLinker Platinum and GeneLinker Diamond. While GeneLinker Gold uses publicly available clustering algorithms, Platinum and Diamond will offer proprietary technology, the company said, declining to give a launch date.

The company said it is offering GeneLinker Gold as an alternative to other commercial products that also repackage publicly available bioinformatics tools at a higher price.

Don Van Dyke, vice president of sales and marketing at Molecular Mining, said that GeneLinker Gold’s list price of $5,000 comes in well below comparable expression analysis packages that can run as high as $25,000 to $30,000.

The company said market research showed there was a lot of demand for entry-level solutions in gene expression analysis, adding that it hoped GeneLinker Gold would help the company to forge an initial relationship with customers that would eventually lead to deals for its proprietary tools.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.